Feed ABVC
AB

ABVC BioPharma, Inc.

ABVC · NASDAQ

$1.09 -3.11% (-$0.03)
1M +53.31%
Market Cap $28.3M
P/E Ratio -
Div. Yield -
ROE 71.47%

Bulios Fair Price

$0.88

19.3% downside

Trenutna cena

$1.09

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica ABVC trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
1/9
Valuation
86 /100
Cheap
P/B 2.75x
P/S -35.61x
EV/EBITDA N/A
Growth
100 /100
Growing
Book val. growth 35.64%
Rev. growth N/A
FCF growth N/A
Profitability
100 /100
Strong
Net margin 992.85%
Op. margin 918.55%
FCF margin 338.08%
Quality
0 /100
Poor
ROE 71.47%
ROA 40.73%
Asset turnover -0.04x
Debt
46 /100
Moderate
Current ratio 0.07x
Int. coverage -53.09x
Debt/Equity 0.17x
Stability
38 /100
Moderate
Rev. volatility 188.64%
EPS volatility 37.31%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ABVC
Online

O podjetju

ABVC BioPharma, Inc. is a biotechnology company focused on researching and developing new therapeutic approaches in the fields of oncology and immunotherapy. The company aims to discover drugs that can target specific immune mechanisms and potentially improve the treatment of various types of cancer. ABVC BioPharma strives to bring innovations to cancer treatment and support patients' immune systems in fighting the disease. Their research is directed towards developing drugs that can intervene in complex biological processes associated with cancer. Investors interested in the biotechnology sector and new therapeutic strategies in oncology might see potential in ABVC BioPharma, Inc. (ABVC) shares for innovation and growth in this field.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Uttam Yashwant Patil

Employees

18

Headquarters

Fremont

Prihajajoči dogodki

16 NOV.

Earnings

Upcoming earnings report

52d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.